References
- EMA (2011). Guideline on missing data in confirmatory clinical trials. European Medicine Agency. Retrieved from https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-missing-data-confirmatory-clinical-trialsen.pdf
- ICH E9 (1998). Statistical principles for clinical trials. Retrieved from https://database.ich.org/sites/default/files/E9Guideline.pdf
- ICH E9 (R1) (2019). Addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials. Retrieved from https://database.ich.org/sites/default/files/E9-R1S/tep4Guideline20191203.pdf16
- Mallinckrodt, C. H., Lane, P. W., Schnell, D., Peng, Y., & Mancuso, J. P. (2008). Recommendations for the primary analysis of continuous endpoints in longitudinal clinical trials. Drug Information Journal, 42(4), 303–319. https://doi.org/10.1177/009286150804200402
- Rubin, D. B. (2008). Multiple imputation after 18+ years (with discussion). Journal of the American Statistical Association, 91(434), 473–489. https://doi.org/10.1080/01621459.1996.10476908
- Shao, J., & Zhong, B. (2003). Last observation carry-forward and last observation analysis. Statistics in Medicine, 22(15), 2429–2441. https://doi.org/10.1002/(ISSN)1097-0258
- Shao, J., & Zhong, B. (2006). On the treatment effect in clinical trials with dropout. Journal of Biopharmaceutical Statistics, 16(1), 25–33. https://doi.org/10.1080/10543400500406488
- Siddiqui, O., Hung, H. M. J., & O'Neill, R. (2009). MMRM vs LOCF: A comprehensive comparison based on simulation study and 25 NDA datasets. Journal of Biopharmaceutical Statistics, 19(2), 227–246. https://doi.org/10.1080/10543400802609797
- Ting, N., Chen, D., Ho, S., & Capppelleri, J. (2017). Phase II clinical development of new drugs. Springer.
- Ting, N., Huang, L., Deng, Q., & Capppelleri, J. (2021). Average response over time as estimand: An alternative implementation of the while on treatment strategy. Statistics in Biosciences, 13, 479–494. https://doi.org/10.1007/s12561-021-09301-x